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Campylobacterfetusbacteremiaisrareandoccursmainlyinpatientswithimmunosuppression.Thisinfection,whichofteninvolves
secondarylocalizationshasalreadybeenreportedinsomeprimaryhumoralimmunedeﬁciencies.Wedescribethreecasesofsevere
infection due to C. fetus with cellulitis at presentation, but without any gastrointestinal symptoms, occurring in patients with
acquired hypogammaglobulinemia.
1.Introduction
Infections due to Campylobacter fetus represent only a small
proportion of Campylobacter infections, usually responsible
for acute diarrhea. C. fetus bacteremia is relatively rare and
occurs mainly against a background of immunosuppression
(diabetes, cirrhosis, AIDS, and elderly patients) [1, 2]. This
severe form of infection that can spread to involve secondary
localizations has been reported in some patients with prima-
ry humoral immune deﬁciencies [3, 4].
We describe three cases of severe infection due to C.
fetus occurring in immunosuppressed patients with acquired
hypogammaglobulinemia.
2.CaseReport
Patient 1. A 77-year-old diabetic man, with chronic lym-
phocytic leukemia (not treated), was hospitalized for sepsis
without any obvious clinical source, notably no diarrhea
syndrome.Hereceivedempiricantibiotherapywithacombi-
nation of ceftriaxone and metronidazole. Apart from known
hyperlymphocytosis (24giga/L), the rest of his hemogram
was unremarkable. There was clear hypogammaglobuline-
mia: IgG = 3.2g/L (normal >6.9g/L) and IgA = 0.4g/L
(normal >0.88g/L). C. fetus was isolated from blood cul-
tures, but not from the fecal culture. Azithromycin was
initiated for a total duration of 2 weeks. One month later,
the patient presented with a novel septic state, this time
associated with abdominal cutaneous cellulitis. C. fetus was
again recovered from blood cultures (5/5 bottles). Initial
antibiotherapy (piperacillin-tazobactam) was again replaced
byazithromycinforadurationof4weeks.Substitutiontreat-
ment with monthly intravenous immunoglobulins (IVIg)
was initiated, and a residual level of 6g/L was obtained. No
relapse was noted after more than 12 months of followup.
Patient 2. A58-year-oldmanwithSHARPsyndrome(mixed
connective tissue disease with predominant autoimmune
myositis) and hypogammaglobulinemia secondary to im-
munosuppressive treatment (cyclophosphamide, mycophe-
nolate mofetil, and rituximab) was hospitalized for sepsis
associated with cellulitis of the left upper arm, without any
obvious clinical source. His hemogram was unremarkable
(neutrophils = 16giga/L). The patient had already received2 Case Reports in Gastrointestinal Medicine
monthly IVIg substitution for 4 years and had an IgG level
of 6g/L and IgA of 1.05g/L at the time of appearance
of the infection. Blood cultures (5/5 bottles) were positive
for C. fetus. The infection responded rapidly to combined
antibiotherapy (piperacillin-tazobactam and azithromycin)
for a duration of 6 weeks. No relapse was noted after a
followup of 19 months.
Patient 3. A 71-year-old woman, followed for several years
with mixed cryoglobulinemia complicating low-grade lym-
phoma, was hospitalized for sepsis at 1 month after her ﬁrst
course of chemotherapy (rituximab-cyclophosphamide and
dexamethasone). The chemotherapy was rapidly followed
by the development of infectious complications includ-
ing pneumopathy and then otitis due to Pneumococcus.
Severe hypogammaglobulinemia (IgG = 2.89g/L and IgA
= 0.64g/L) led to substitution treatment with IVIg. One
month later, in the absence of neutropenia, she presented
with cellulitis of the left leg with reactional arthritis of
the homolateral knee (IgG = 5.25g/L at that time). Blood
cultures were positive for C. fetus (2/2 bottles). She was
successfully treated with ceftriaxone 2g/day followed by oral
ciproﬂoxacin (1000mg/day) for a total duration of 3 weeks.
TreatmentwithIVIgwascontinuedwiththeaimofachieving
ar e s i d u a ll e v e lo f>6g/L, but at 2 months she presented with
a new episode of severe sepsis due to Escherichia coli leading
to death.
3. Discussion
We report three cases of severe C. fetus bacteremia devel-
oping in the setting of acquired immunosuppression with
hypogammaglobulinemia. These “opportunistic” infections
are a real concern for the clinician since Campylobacter
bacteremia often involves extraintestinal localizations [1, 2,
5]. C. fetus, which is not the most common Campylobacter
species identiﬁed in the general population, is more often
found in immunosuppressed patients where it represents
more than one-half of cases [2]. As in our patients, this
species also appears to be more common in elderly patients,
as reported by Pacanowski et al. (median age 69.5 years
versus 55.6 for other species of Campylobacter)[ 2].
Since the introduction of tritherapy, the number of
c a s e sr e p o r t e di nc o n n e c t i o nw i t hH I Vh a sb e e ns u p e r s e d e d
by those occurring in other types of immunosuppression,
particularly in subjects with humoral immune deﬁciencies.
The ﬁrst case reported in the literature concerned a 50-
year-old patient with Good’s syndrome who presented with
bacteremia due to C. fetus postthymectomy [1]. Other stud-
ies then demonstrated the association between hypogam-
maglobulinemia and infection with diﬀerent Campylobacter
species [2]. More recently, Oksenhendler et al. found 19
cases of common variable immunodeﬁciency (CVID) in a
series of 252 Campylobacter infections, and measurement
of immunoglobulins in these patients revealed undetectable
levels of IgA and IgM [4]. This hypogammaglobulinemia,
which usually aﬀects IgA, could favor C. fetus infections due
to the important role of these immunoglobulins in the anti-
infectious defense of the body at the level of the digestive
mucous membranes.
The digestive tract is the usual route of contamination
by C. fetus, yet digestive symptoms such as diarrhea are not
always present (less than one patient in two). This may divert
the clinician away from the diagnosis and explains in part
why the diagnosis is most often made from blood cultures
and not from fecal cultures [2, 5]. This absence of digestive
signs associated with atypical symptoms such as cellulitis are
characteristics of C. fetus infection reported in the literature
[2, 5]. In the cohort reported by Pacanowski et al., diarrhea
was found in only 33% of cases and cellulitis in 19% (versus
7% cellulitis for the other Campylobacter species) [2]. These
data agree with the clinical presentation in our three patients
who all presented with cellulitis-type cutaneous symptoms,
without any digestive signs.
The evolution of the patients in terms of mortality
depends on the underlying disease and also on the initial
choice (adapted or not) of antibiotherapy. C. fetus is often
resistant to quinolones and macrolides, and some authors
recommend the use of imipenems as ﬁrst-line treatment
[1, 2]. In the series of 178 patients described by Pacanowski
et al., no strain of C. fetus was resistant to imipenems,
while 32% were resistant to ﬂuoroquinolones, and no
patient on imipenem had died at 30-day followup [2]. In
contrast, resistance to erythromycin and the combination
amoxicillin-clavulanic acid was more often found with other
Campylobacter species [2].
Bacteremia due to C. fetus readily recurs with atypical
symptoms and requires prolonged antibiotherapy [2, 5].
Multiple factors, including the duration of antibiotherapy,
probably favor these relapses, but hypogammaglobulinemia
could also be a risk factor for relapse even in cases of
prolonged antibiotherapy [1]. Some studies have demon-
strated that resistance of the bacteria is due to a defect in
opsonization. The impact of substitution treatment with
IVIg is poorly understood, especially as the IgA deﬁcit is not
corrected by this therapy.
Our three cases illustrate both the atypical presentation
with absence of gastrointestinal symptoms and the potential
risk of severe C. fetus infections in the context of hemato-
logicalorrheumatologicconditionswithacquiredhypogam-
maglobulinemia. Actually, C. Fetus bacteremia should be
suspected among any immunocompromised patients with
gastrointestinalsymptoms,aswellasamongthosepresenting
with cellulitis but no diarrhea.
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